KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

AbCellera Biologics (ABCL) EBIT Margin: 2020-2023

Historic EBIT Margin for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -719.61%.

  • AbCellera Biologics' EBIT Margin fell 54427.00% to -719.61% in Q4 2023 from the same period last year, while for Dec 2023 it was -623.80%, marking a year-over-year decrease of 66840.00%. This contributed to the annual value of -1,091.69% for FY2024, which is 46787.00% down from last year.
  • As of Q4 2023, AbCellera Biologics' EBIT Margin stood at -719.61%, which was up 13.49% from -831.79% recorded in Q3 2023.
  • AbCellera Biologics' EBIT Margin's 5-year high stood at 77.97% during Q1 2021, with a 5-year trough of -831.79% in Q3 2023.
  • Its 3-year average for EBIT Margin is -256.58%, with a median of -100.39% in 2021.
  • In the last 5 years, AbCellera Biologics' EBIT Margin surged by 54,731bps in 2022 and then slumped by 86,901bps in 2023.
  • Quarterly analysis of 4 years shows AbCellera Biologics' EBIT Margin stood at 77.33% in 2020, then tumbled by 1,880bps to 58.53% in 2021, then crashed by 23,388bps to -175.34% in 2022, then slumped by 54,427bps to -719.61% in 2023.
  • Its last three reported values are -719.61% in Q4 2023, -831.79% for Q3 2023, and -511.03% during Q2 2023.